IDDM12
MCID: DBT082
MIFTS: 36

Diabetes Mellitus, Insulin-Dependent, 12 (IDDM12) malady

Categories: Genetic diseases, Metabolic diseases, Rare diseases, Endocrine diseases

Aliases & Classifications for Diabetes Mellitus, Insulin-Dependent, 12

Aliases & Descriptions for Diabetes Mellitus, Insulin-Dependent, 12:

Name: Diabetes Mellitus, Insulin-Dependent, 12 54 66 69
Insulin-Dependent Diabetes Mellitus 12 12 66 29
Type 1 Diabetes Mellitus 12 12 14
Iddm12 12 66

Classifications:



External Ids:

OMIM 54 601388
Disease Ontology 12 DOID:0110751
ICD10 33 E10
MedGen 40 C1832392
MeSH 42 D003922

Summaries for Diabetes Mellitus, Insulin-Dependent, 12

UniProtKB/Swiss-Prot : 66 Diabetes mellitus, insulin-dependent, 12: A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

MalaCards based summary : Diabetes Mellitus, Insulin-Dependent, 12, also known as insulin-dependent diabetes mellitus 12, is related to complement component 8 deficiency and autosomal dominant intermediate charcot-marie-tooth. An important gene associated with Diabetes Mellitus, Insulin-Dependent, 12 is CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Allograft rejection. The drugs Febuxostat and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include eye and kidney.

Disease Ontology : 12 A type 1 diabetes mellitus that has material basis in mutation of the CTLA4 gene on chromosome 2q33.2.

Description from OMIM: 601388

Related Diseases for Diabetes Mellitus, Insulin-Dependent, 12

Diseases in the Diabetes Mellitus, Insulin-Dependent family:

Diabetes Mellitus, Insulin-Dependent, 19 Diabetes Mellitus, Insulin-Dependent, 7
Diabetes Mellitus, Insulin-Dependent, 12 Diabetes Mellitus, Insulin-Dependent, 13
Diabetes Mellitus, Insulin-Dependent, 22 Diabetes Mellitus, Insulin-Dependent, 23
Diabetes Mellitus, Insulin-Dependent, 18 Diabetes Mellitus, Insulin-Dependent, 15
Diabetes Mellitus, Insulin-Dependent, 21 Diabetes Mellitus, Insulin-Dependent, 5
Diabetes Mellitus, Insulin-Dependent, 8 Diabetes Mellitus, Insulin-Dependent, 24
Diabetes Mellitus, Insulin-Dependent, 17 Diabetes Mellitus, Insulin-Dependent, 2
Diabetes Mellitus, Insulin-Dependent, 4 Diabetes Mellitus, Insulin-Dependent, 20
Diabetes Mellitus, Insulin-Dependent, 11 Diabetes Mellitus, Insulin-Dependent, 3
Diabetes Mellitus, Insulin-Dependent, 6

Diseases related to Diabetes Mellitus, Insulin-Dependent, 12 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 29)
id Related Disease Score Top Affiliating Genes
1 complement component 8 deficiency 10.1 CTLA4 HLA-DRB1
2 autosomal dominant intermediate charcot-marie-tooth 10.1 CTLA4 HLA-DRB1
3 angiomatosis, diffuse corticomeningeal, of divry and van bogaert 10.1 CTLA4 HLA-DRB1
4 kernicterus due to isoimmunization 10.1 CTLA4 HLA-DRB1
5 hepatitis 10.1 CTLA4 HLA-DRB1
6 non-amyloid monoclonal immunoglobulin deposition disease 10.1 HLA-DRB1 SLC11A1
7 low anorectal malformation 10.1 CTLA4 HLA-DRB1
8 b-cell lymphomas 10.0 CTLA4 HLA-DRB1
9 nystagmus, congenital motor, autosomal recessive 10.0 HLA-DRB1 SLC11A1
10 pleuropulmonary blastoma 10.0 CTLA4 INS
11 denys-drash syndrome 10.0 CTLA4 INS
12 prostatic urethral cancer 10.0 CTLA4 INS
13 paroxysmal nonkinesigenic dyskinesia 2 10.0 INS SLC11A1
14 deafness, autosomal recessive 67 10.0 HLA-DRB1 SLC11A1
15 pulsating exophthalmos 10.0 CTLA4 HLA-DRB1
16 glomangiomyoma 9.9 CTLA4 INS
17 periarthritis 9.9 HLA-DRB1 SLC11A1
18 erythematosquamous dermatosis 9.9 HLA-DRB1 SLC11A1
19 intracranial hemorrhage in brain cerebrovascular malformations 9.9 HLA-DRB1 SLC11A1
20 neutral lipid storage disease with myopathy 9.8 CTLA4 FGF3 INS
21 breast cancer 9.8 CTLA4 INS SLC11A1
22 graves' disease 9.8
23 thyroiditis 9.8
24 rheumatoid arthritis 9.8 CTLA4 HLA-DRB1 SLC11A1
25 atrial septal defect 6 9.8 HLA-DRB1 SLC11A1
26 articulation disorder 9.8 CTLA4 HLA-DRB1 INS
27 diabetes mellitus, insulin-dependent, 8 9.6 CTLA4 FGF3 INS SUMO4
28 diabetes mellitus, insulin-dependent, 20 9.6 CTLA4 HLA-DRB1 INS SUMO4
29 celiac disease 3 9.2 CTLA4 FGF3 HLA-DRB1 INS SLC11A1 SUMO4

Graphical network of the top 20 diseases related to Diabetes Mellitus, Insulin-Dependent, 12:



Diseases related to Diabetes Mellitus, Insulin-Dependent, 12

Symptoms & Phenotypes for Diabetes Mellitus, Insulin-Dependent, 12

Clinical features from OMIM:

601388

Drugs & Therapeutics for Diabetes Mellitus, Insulin-Dependent, 12

Drugs for Diabetes Mellitus, Insulin-Dependent, 12 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 332)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Febuxostat Approved Phase 4 144060-53-7 134018
2
Nitric Oxide Approved Phase 4 10102-43-9 145068
3
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
4
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
5
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
6
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
7
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1 116094-23-6 16132418
8
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1 160337-95-1
9
Insulin-glulisine Approved Phase 4,Phase 3,Phase 2 207748-29-6
10
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1 133107-64-9
11
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1 169148-63-4 5311023
12
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
13
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
14
Norepinephrine Approved Phase 4 51-41-2 439260
15
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
16
Exenatide Approved, Investigational Phase 4,Phase 2 141758-74-9 15991534
17
Gliclazide Approved Phase 4 21187-98-4 3475
18
Inulin Approved, Nutraceutical Phase 4,Early Phase 1 9005-80-5 24763
19
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3 67-97-0 6221 10883523 5280795
20
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3 50-14-6 5280793
21
Uric Acid Experimental, Investigational Phase 4 69-93-2 1175
22
Angiotensin II Phase 4 68521-88-0, 11128-99-7 65143 172198
23 Angiotensinogen Phase 4
24 Antioxidants Phase 4,Phase 3,Phase 1,Phase 2
25 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1
26 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2
27 gastric inhibitory polypeptide Phase 4
28 glucagon Phase 4,Phase 3,Phase 2,Phase 1
29 Glucagon-Like Peptide 1 Phase 4,Phase 3,Phase 2,Phase 1
30 Hormones Phase 4,Phase 3,Phase 2,Phase 1
31 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Incretins Phase 4,Phase 3,Phase 2,Phase 1
33 insulin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Dipeptidyl-Peptidase IV Inhibitors Phase 4,Phase 2
38 HIV Protease Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
39 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
41
protease inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
42 Sitagliptin Phosphate Phase 4,Phase 2
43 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
44 Ergocalciferols Phase 4,Phase 3
45 Hydroxycholecalciferols Phase 4
46 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
47 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
48 vitamin d Phase 4,Phase 3
49 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
50 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 377)
id Name Status NCT ID Phase
1 The Effect of Uric Acid Lowering in Type 1 Diabetes Unknown status NCT02344602 Phase 4
2 Mixed Meal Test in Type 1 Diabetes on Insulin Pump Therapy: Optimization of Artificial Pancreas Unknown status NCT02003274 Phase 4
3 Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Unknown status NCT01800734 Phase 4
4 The Effect of Supplementation With Two Different Doses of Vitamin D on Bone Mineral Density, Vitamin D Levels and Hand Grip Strength in Children With Diabetes Mellitus Type 1 Completed NCT01277913 Phase 4
5 Effect of CSII and CGM on Progression of Late Diabetic Complications Completed NCT01454700 Phase 4
6 Apidra Children & Adolescents Study Completed NCT01202474 Phase 4
7 Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes Completed NCT00660998 Phase 4
8 Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet Completed NCT00118937 Phase 4
9 baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus Completed NCT01204593 Phase 4
10 SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1 Completed NCT00313937 Phase 4
11 A Study for Patients With Diabetes Mellitus (IOPA) Completed NCT00420095 Phase 4
12 Comparing the Metabolic Control of Once to Twice-daily Insulin Detemir Injections Completed NCT00542399 Phase 4
13 Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Completed NCT00964574 Phase 4
14 Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment Completed NCT01099618 Phase 4
15 APIDRA Registration Study Completed NCT00489190 Phase 4
16 Effectiveness Study of the Guardian RT in Type 1 Diabetics Completed NCT01331343 Phase 4
17 Influence of Diabetes on Tramadol Pharmacokinetics Completed NCT02246712 Phase 4
18 Protection Against Pneumococcal Infection in Children With T1DM Completed NCT01939522 Phase 4
19 New Onset Type 1 Diabetes: Role of Exenatide Recruiting NCT01269034 Phase 4
20 Renoprotective Effects of Dapagliflozin in Type 2 Diabetes Recruiting NCT02682563 Phase 4
21 Fat and Protein Study Recruiting NCT02680054 Phase 4
22 The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial Active, not recruiting NCT01834144 Phase 4
23 Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia Active, not recruiting NCT02192450 Phase 4
24 Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Enrolling by invitation NCT02914886 Phase 4
25 Autoimmune Diabetes Accelerator Prevention Trial Enrolling by invitation NCT02881528 Phase 4
26 Probiotics in Newly Recognized Type 1 Diabetes Not yet recruiting NCT03032354 Phase 4
27 An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes Not yet recruiting NCT02962492 Phase 4
28 Prospective Assessment of Meos Telemedicine E-portal on Ambulatory Care of Type 1 Diabetic Patients Unknown status NCT01447940 Phase 3
29 Intranasal Insulin for Prevention of Type 1 Diabetes Unknown status NCT00223613 Phase 3
30 Metformin Therapy for Overweight Adolescents With Type 1 Diabetes Unknown status NCT01881828 Phase 3
31 A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume Unknown status NCT01320345 Phase 3
32 Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin Unknown status NCT00668850 Phase 3
33 A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus Completed NCT01792284 Phase 3
34 Liraglutide in the Treatment of Type 1 Diabetes Mellitus Completed NCT01722266 Phase 3
35 12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes. Completed NCT00046150 Phase 3
36 Study of Insulin Therapy Augmented by Real Time Sensor IN Type 1 Children and Adolescents (START-IN!) Completed NCT00949221 Phase 2, Phase 3
37 Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes Completed NCT00447382 Phase 3
38 Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus Completed NCT01683266 Phase 3
39 Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use Completed NCT01134107 Phase 3
40 Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults Completed NCT01103284 Phase 3
41 Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles Completed NCT00871416 Phase 3
42 Liraglutide as add-on to Insulin in Type 1 Diabetes Completed NCT02092896 Phase 3
43 A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003) Completed NCT02059161 Phase 3
44 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes Completed NCT00993473 Phase 3
45 Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine Completed NCT02273180 Phase 3
46 The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus Completed NCT00385697 Phase 2, Phase 3
47 Insulin Clamp Ancillary Study for Assessment of Insulin Resistance Completed NCT02045290 Phase 3
48 Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients Completed NCT00615264 Phase 3
49 Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial Completed NCT01788527 Phase 3
50 Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes Completed NCT00474045 Phase 3

Search NIH Clinical Center for Diabetes Mellitus, Insulin-Dependent, 12

Genetic Tests for Diabetes Mellitus, Insulin-Dependent, 12

Genetic tests related to Diabetes Mellitus, Insulin-Dependent, 12:

id Genetic test Affiliating Genes
1 Diabetes Mellitus, Insulin-Dependent, 12 29

Anatomical Context for Diabetes Mellitus, Insulin-Dependent, 12

MalaCards organs/tissues related to Diabetes Mellitus, Insulin-Dependent, 12:

39
Eye, Kidney

Publications for Diabetes Mellitus, Insulin-Dependent, 12

Variations for Diabetes Mellitus, Insulin-Dependent, 12

Expression for Diabetes Mellitus, Insulin-Dependent, 12

Search GEO for disease gene expression data for Diabetes Mellitus, Insulin-Dependent, 12.

Pathways for Diabetes Mellitus, Insulin-Dependent, 12

GO Terms for Diabetes Mellitus, Insulin-Dependent, 12

Cellular components related to Diabetes Mellitus, Insulin-Dependent, 12 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 late endosome membrane GO:0031902 8.62 HLA-DRB1 SLC11A1

Biological processes related to Diabetes Mellitus, Insulin-Dependent, 12 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.33 CTLA4 HLA-DRB1 SLC11A1
2 wound healing GO:0042060 9.26 INS SLC11A1
3 T cell costimulation GO:0031295 8.96 CTLA4 HLA-DRB1
4 negative regulation of T cell proliferation GO:0042130 8.62 CTLA4 HLA-DRB1

Sources for Diabetes Mellitus, Insulin-Dependent, 12

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....